Efficacy and Safety of Everolimus in Patients with Non-Clear Cell Renal Cell Carcinoma
Phase 2
- Conditions
- on-clear cell renal cell carcinoma
- Registration Number
- JPRN-UMIN000006248
- Lead Sponsor
- Yamaguchi University Graduate School of Medicine , Department of Urology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients with history of hypersensitivity against everolimus or sirolimus derivative 2) Pregnant, pregnancy suspect, nursing women, patients who plan to have a baby 3) Patients who are on long-term treatment with corticosteroid or immunosuppressant 4) Patients treated for another primary malignancy within 3 years of enrollment 5) Patients judged ineligible to participate in the study by the investigator
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How does mTOR inhibition by everolimus affect tumor progression in non-clear cell renal cell carcinoma subtypes?
What comparative efficacy data exist for everolimus versus tyrosine kinase inhibitors in nccRCC treatment?
Which biomarkers correlate with response to mTOR pathway inhibition in JPRN-UMIN000006248 observational trial?
What are the long-term safety profiles of everolimus in nccRCC patients compared to sirolimus or temsirolimus?
How do combination therapies involving everolimus and immune checkpoint inhibitors impact nccRCC outcomes?